Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Kindred Biosciences announces results from pilot study of KIND-025 » 08:34
03/24/20
03/24
08:34
03/24/20
08:34
KIN

Kindred Biosciences

$3.26 /

-0.375 (-10.33%)

Kindred Biosciences…

Kindred Biosciences announced positive results from its pilot field efficacy study of KIND-025, a canine fusion protein targeting interleukin-4 and interleukin-13, for the treatment of atopic dermatitis in dogs. The study was a randomized, blinded, placebo-controlled pilot effectiveness study that enrolled 26 client-owned dogs diagnosed with atopic dermatitis to assess the efficacy, safety, and pharmacokinetic profile of KIND-025. A single dose of KIND-025 or placebo was administered on day 0, and the severity of pruritus and atopic dermatitis were assessed at day 0 and weeks 1, 2, 3 and 4. Treatment success for individual dogs at each visit was defined as a 50% or higher reduction from baseline in CADESI-4 or PVAS scores. Higher success rate was observed in the KIND-025 group over the placebo group from week 1 through week 4. Positive efficacy signals were also detected with other endpoints including 20mm or higher reduction from baseline in PVAS score.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Stifel animal health analysts to hold an analyst/industry conference call » 13:55
03/19/20
03/19
13:55
03/19/20
13:55
TRUP

Trupanion

$26.73 /

+0.67 (+2.57%)

, KIN

Kindred Biosciences

$5.20 /

+1.785 (+52.35%)

, CVT

Cvent

$0.00 /

+ (+0.00%)

, IDXX

Idexx Laboratories

$195.84 /

-10.15 (-4.93%)

, ZTS

Zoetis

$104.70 /

-1.33 (-1.25%)

Analysts discuss the…

Analysts discuss the Animal Health Industry and their expectations that there will be some impact to the industry growth in the 2Q20 due to COVID-19 on an Analyst/Industry conference call to be held on March 19 at 2:30 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Stifel animal health analysts to hold an analyst/industry conference call » 10:03
03/19/20
03/19
10:03
03/19/20
10:03
TRUP

Trupanion

$25.44 /

-0.62 (-2.38%)

, KIN

Kindred Biosciences

$3.31 /

-0.1 (-2.93%)

, CVT

Cvent

$0.00 /

+ (+0.00%)

, IDXX

Idexx Laboratories

$191.87 /

-14.12 (-6.85%)

, ZTS

Zoetis

$102.95 /

-3.08 (-2.90%)

Analysts discuss the…

Analysts discuss the Animal Health Industry and their expectations that there will be some impact to the industry growth in the 2Q20 due to COVID-19 on an Analyst/Industry conference call to be held on March 19 at 2:30 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim » 06:58
03/17/20
03/17
06:58
03/17/20
06:58
KIN

Kindred Biosciences

$6.01 /

-0.825 (-12.08%)

Guggenheim analyst David…

Guggenheim analyst David Westenberg downgraded Kindred Biosciences to Neutral from Buy.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Kindred Biosciences reports Q4 EPS (40c), consensus (36c) » 16:05
03/16/20
03/16
16:05
03/16/20
16:05
KIN

Kindred Biosciences

$6.02 /

-0.81 (-11.86%)

Reports Q4 revenue $1.4M,…

Reports Q4 revenue $1.4M, consensus $1.3M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Kindred Biosciences to sell Mirataz to Dechra Pharmaceuticals for $43M upfront » 16:04
03/16/20
03/16
16:04
03/16/20
16:04
KIN

Kindred Biosciences

$6.06 /

-0.775 (-11.35%)

Kindred Biosciences…

Kindred Biosciences announced that it has entered into a transaction for the sale of Mirataz to Dechra Pharmaceuticals for an upfront payment of $43M and royalties on worldwide sales. In addition, the company announced that it will substantially reduce its commercial footprint. This, along with partnership deals, is expected to significantly reduce the amount of additional dilutive capital the company will require. In addition, the company will further prioritize biologics programs for dogs and cats, and discontinue development of canine and feline small molecule programs.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research » 09:48
03/13/20
03/13
09:48
03/13/20
09:48
ZTS

Zoetis

$124.75 /

+4.3 (+3.57%)

, IDXX

Idexx Laboratories

$245.01 /

+5.18 (+2.16%)

Cleveland Research…

Cleveland Research analyst Rob Eich tells investors that Zoetis (ZTS) has started taking preorders on Simparica Trio this week, adding that demand for the product appears robust and channel expectations are for Trio to take significant share. The analyst says he is hearing internal expectations for Simparica Trio are around $175M in global sales in 2020 and is also hearing Zoetis is contemplating giving a product they current sell direct to distribution if they meet Simparica Trio goals which is driving further excitement from distribution. He thinks Zoetis is likely to roll out a combined reference lab offering in 2021 which is expected to have no contracts and low pricing and expects this to be disruptive to Idexx (IDXX).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Idexx Laboratories says sees no COVID-19 cases in pets » 07:33
03/13/20
03/13
07:33
03/13/20
07:33
IDXX

Idexx Laboratories

$239.83 /

-5.74 (-2.34%)

Idexx Laboratories…

Idexx Laboratories announced that the company has seen no positive results in pets to date of SARS-CoV-2, the coronavirus strain responsible for the coronavirus disease 2019 (COVID-19) respiratory outbreak in humans. Idexx evaluated thousands of canine and feline specimens during validation of a new veterinary test system for the COVID-19 virus. The specimens used for test development and validation were obtained from specimens submitted to Idexx Reference Laboratories for PCR testing. These new test results align with the current expert understanding that COVID-19 is primarily transmitted person-to-person and supports the recommendation against testing pets for the COVID-19 virus.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Periodicals
Kindred Biosciences exploring strategic options, Dealreporter says » 13:37
02/28/20
02/28
13:37
02/28/20
13:37
KIN

Kindred Biosciences

$9.37 /

-0.46 (-4.68%)

Kindred Biosciences is…

Kindred Biosciences is exploring strategic options, including a potential sale, with the assistance of advisor Barclays, according to Dealreporter, citing sources familiar with the matter. The pet medicine company has been fielding interest from potential suitors for several months, the report said, according to Fly contacts.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
BofA/Merrill to hold a summit » 07:51
02/24/20
02/24
07:51
02/24/20
07:51
ELAN

Elanco

$31.16 /

+0.935 (+3.09%)

, IDXX

Idexx Laboratories

$278.55 /

-2.92 (-1.04%)

, KIN

Kindred Biosciences

$10.25 /

+0.85 (+9.04%)

, PETZ

TDH Holdings

$1.46 /

-0.1 (-6.41%)

, ZTS

Zoetis

$142.14 /

-1.39 (-0.97%)

Animal Health Summit to…

Animal Health Summit to be held in New York on February 24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.